Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3905-3912
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3905
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3905
Table 3 Changes in T lymphocyte subsets before and after treatment
| Subset | Baseline | After treatment | P value |
| CD3+ (%) | |||
| Median (range) | 62.5 (45.0-75.0) | 70.0 (50.0-85.0) | < 0.05 |
| CD4+ (%) | |||
| Median (range) | 30.0 (20.0-45.0) | 40.0 (25.0-55.0) | < 0.05 |
| CD8+ (%) | |||
| Median (range) | 28.5 (15.0-40.0) | 22.0 (10.0-35.0) | < 0.05 |
| CD4+/CD8+ ratio | |||
| Median (range) | 1.2 (0.6-2.5) | 1.8 (0.8-3.5) | < 0.05 |
- Citation: Zheng CW, Yang YM, Yang H. Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer. World J Gastrointest Oncol 2024; 16(9): 3905-3912
- URL: https://www.wjgnet.com/1948-5204/full/v16/i9/3905.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i9.3905